Bausch + Lomb eyes AU$1.2 billion in IPO
Ophthalmic giant Bausch + Lomb (B+L), which is being spun-off from its parent as a pure-play eye health company, has ...
Tag: Bausch + Lomb
Eyecare spin-off Bausch + Lomb files for IPO
Almost 18 months since its parent company announced Bausch + Lomb (B+L) would be spun off as a pure-play eye ...
In pursuit of more precise vitrectomy
Vitrectomy cutters are the fundamental tool for vitreoretinal surgeons. South Australian retinal specialist DR STEWART LAKE discusses one of the ...
Rethinking what’s possible with the enVista IOL
Bausch + Lomb’s latest version of the enVista monofocal recently became available to Australian and New Zealand surgeons along with ...
Twin licensing deals bolster Bausch + Lomb’s myopia portfolio
Bausch + Lomb has acquired an exclusive license for a novel myopia control contact lens developed by a Sydney ophthalmic ...
TGA approves ‘breakthrough’ B+L contact lens
Bausch + Lomb has obtained regulatory approval to supply its new Ultra One Day daily disposable silicone hydrogel (SiHy daily) ...
Most trusted industry brands revealed
Specsavers, OPSM and Bausch + Lomb have featured in the eyecare categories of the 2020 Australian Trusted Brands Survey, while ...